Optimal management of peripheral arterial disease for the non-specialist

Ulster Medical Journal

Volumn 80, Issue 1, 2011, Pages 33-41

  O'Donnell, M E ^a,b   Reid, J A ^a   Lau, L L ^a   Hannon, R J ^a   Lee, B ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Epidemiology; Investigation; Peripheral arterial disease; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CINNARIZINE; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOSITOL NICOTINATE; NAFTIDROFURYL OXALATE; PENTOXIFYLLINE; PLACEBO;

ALTERNATIVE MEDICINE; ANTIHYPERTENSIVE THERAPY; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOVASCULAR SURGERY; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INTERMITTENT CLAUDICATION; MAGNETIC RESONANCE ANGIOGRAPHY; PATIENT CARE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL CIRCULATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; SEX DIFFERENCE; SMOKING;

ANKLE BRACHIAL INDEX; DIAGNOSIS, DIFFERENTIAL; DIAGNOSTIC IMAGING; EXERCISE TEST; HUMANS; LEG; NORTHERN IRELAND; PERIPHERAL VASCULAR DISEASES; RISK FACTORS;

EID: 79954520110     PISSN: 00416193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson O, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vasc Surg. 2007;45(6):1185-1191.
2. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 (Suppl 1): S1-S75.
3. Schmieder FA, Comerota AJ. Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies. Amer J Cardiol. 2001;87(12A): 3D-13D.
4. McDermott MM. The magnitude of the problem of peripheral arterial disease: epidemiology and clinical significance. Cleve Clin J Med. 2006;73 (Suppl 4): S2-S7.
5. Second European Consensus Document on chronic critical leg ischaemia. Eur J Vasc Surg. 1992;6 (Supp A): 1-32.
6. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA. 2006;295(5):547-553.
7. Hiatt WR, Nehler MR. Peripheral arterial disease. Adv Int Med. 2001;47: 89-110.
8. Hooi JD, Kester AD, Stoffers HE, Overdijk MM, van Ree JW, Knottnerus JA. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol. 2001;153(7): 666-672.
9. Leng GC, Lee AJ, Fowkes FG, Whiteman M, Dunbar J, Housley E, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. In J Epidemiol. 1996;25(6): 1172-1181.
10. Hiatt WR. Pharmacologic therapy for peripheral arterial disease and claudication. J Vasc Surg, 2002;36(6): 1283-1291.
11. Hooi JD, Stoffers HE, Knottnerus JA, van Ree JW. The prognosis of non-critical limb ischaemia: a systematic review of population-based evidence. Br J Gen Pract, 1999;49(438): 49-55.
12. Dormandy J, Heeck L, Vig S. Predictors of early disease in the lower limbs. Semin Vasc Surg. 1999;12(2):109-117.
13. Hooi JD, Kester AD, Stoffers HE, Rinkens PE, Knottnerus JA, van Ree JW. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin Epidemiol. 2004;57(3):294-300.
14. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110(6):738-743.
15. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from The Framingham Heart Study. Circulation. 1997;96(1): 44-49.
16. Willigendael EM, Teijink JA, Bartelink ML, Kuiken BW, Boiten J, Moll FL, et al. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004;40(6):1158-1165.
17. Kreines K, Johnson E, Albrink M, Knatterud GL, Levin ME, Lewitan A, et al. The course of peripheral vascular disease in non-insulindependent diabetes. Diabetes Care. 1985;8(3):235-243.
18. Elhadd T, Robb R, Jung R, Stonebridge P, Belch J. Pilot study of prevalence of asymptomatic peripheral arterial occlusive disease in patients with diabetes attending a hospital clinic. Pract Diabetes Int. 1999;16(6):163-166.
19. Caputo GM, Cavanagh PR, Ulbrecht JS, Gibbons GW, Karchmer AW. Assessment and management of foot disease in patients with diabetes. New Eng J Med. 1994;331(13):854-860.
20. Sharma M, Rai SK, Tiwari M, Chandra R. Effect of hyperhomocysteinemia on cardiovascular risk factors and initiation of atherosclerosis in Wistar rats. Eur J Pharmacol. 2007;574(1):49-60.
21. Koelemay MJ, Legemate DA, Reekers JA, Koedam NA, Balm R, Jacobs MJ. Interobserver variation in interpretation of arteriography and management of severe lower leg arterial disease. Eur J Vasc Endovasc Surg. 2001;21(5):417-422.
22. Ota H, Takase K, Igarashi K, Chiba Y, Haga K, Saito H, et al. MDCT compared with digital subtraction angiography for assessment of lower extremity arterial occlusive disease: importance of reviewing cross-sectional images. AJR Am J Roentgenol. 2004;182(1): 201-209.
23. Morgan MB, Crayford T, Murrin B, Fraser SC. Developing the Vascular Quality of Life Questionnaire: a new disease-specific quality of life measure for use in lower limb ischemia. J Vasc Surg. 2001;33(4):679-687.
24. Mehta T, Venkata Subramaniam A, Chetter I, McCollum P. Diseasespecific quality of life assessment in intermittent claudication: review. Eur J Vasc Endovasc Surg. 2003;25(3):202-208.
25. Regensteiner JG, Ware JE, Jr., McCarthy WJ, Zhang P, Forbes WP, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc. 2002;50(12):1939-1946.
26. Badger SA, Soong CV, O'Donnell ME, Boreham CA, McGuigan KE. Benefits of a supervised exercise program after lower limb bypass surgery. Vasc Endovascul Surg. 2007;41(1):27-32.
27. Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90(12):1314-1319.
28. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation. 1995;92(3): 614-621.
29. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285(19): 2486-2497.
30. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database of Systematic Reviews (Online). 2008(2): CD000165.
31. Ernst E, Fialka V. A review of the clinical effectiveness of exercise therapy for intermittent claudication. Arch Int Med. 1993;153(20):2357-2360.
32. Lord SR, Lloyd DG, Nirui M, Raymond J, Williams P, Stewart RA. The effect of exercise on gait patterns in older women: a randomized controlled trial. J Gerontol A Biol Sci Med Sci. 1996;51(2): M64-M70.
33. Antithrombotic Trialist's Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
34. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348(9038):1329-1339.
35. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of Cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7-22.
36. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108(12):1481-1486.
37. Reid JA, Wolsley C, Lau LL, Hannon RJ, Lee B, Young IS, et al. The effect of pravastatin on intima media thickness of the carotid artery in patients with normal cholesterol. Eur J Vasc Endovasc Surg. 2005;30(5):464-468.
38. Yusef S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study (HOPES) Investigators. N Eng J Med. 2000;342:145-153.
39. Lip GY, Makin AJ. Treatment of hypertension in peripheral arterial disease. Cochrane Database Systematic Reviews (Online) 2009(4): CD003075.
40. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Int Med. 1991;151(9):1769-1776.
41. Liu Y, Shakur Y, Yoshitake M, Kambayashi Ji J. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev. 2001;19(4):369-386.
42. Dean SM. Pharmacologic treatment for intermittent claudication. Vasc Med. 2002;7(4):301-309.
43. Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs. 2003;3(2): 117-138.
44. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database of Systematic Reviews (Online) 2008(1): CD003748.
45. O'Donnell ME, Badger SA, Sharif MA, Young IS, Lee B, Soong CV. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg. 2009;49(5):1226-1234.
46. O'Donnell ME, Badger SA, Sharif MA, Makar RR, Young IS, Lee B, et al. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. Vasc Endovascular Surg. 2009;43(2):132-143.
47. Lehert P, Comte S, Gamand S, Brown TM. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 1994;23(Suppl 3): S48-S52.
48. Scottish Collegiate Guidelines Network (SIGN) Diagnosis and Management of Peripheral Arterial Disease - A National Clinical Guideline. Edinburgh: SIGN; 2006. Available online from: http://www.sign.ac.uk/pdf/sign89.pdf. Last accessed November 2010.
49. Van Neuten JM, Janssen PA. Effect of cinnarizine on peripheral circulation in dogs. Eur J Pharmacol. 1972;17(1): 103-106.
50. Balsano F, Coccheri S, Libretti A, Nenci GG, Catalano M, Fortunato G, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med. 1989;114(1):84-91.
51. Horsch S, Walther C. Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD)--a review based on randomized, controlled studies. Int J Clin Pharmacol Ther. 2004;42(2):63-72.
52. Lederman RJ, Mendelsohn FO, Anderson RD, Saucedo JF, Tenaglia AN, Hermiller JB, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet. 2002;359(9323):2053-2058.
53. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360(9331): 427-435.
54. Rajagopalan S, Olin J, Deitcher S, Pieczek A, Laird J, Grossman PM, et al. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation. 2007;115(10): 1234-1243.
55. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. New England J Med. 2006;354(15):1567-1577.
56. Becker GJ, Katzen BT, Dake MD. Noncoronary angioplasty. Radiology. 1989;170(3 Pt 2): 921-940.
57. Rutherford R, Durham J. Percutaneous balloon angioplasty for arteriosclerosis obliterans: long term results. In: Yao J, Pearce W, editors. Techniques in Vascular Surgery, Philadelphia: Saunders; 1992. p. 329-345.
58. Fowkes G, Gillespie IN. Angioplasty (versus non surgical management) for intermittent claudication. Cochrane Database of Systematic Reviews (Online) 1998(2): CD000017.
59. de Vries SO, Hunink MG. Results of aortic bifurcation: a metaanalysis. J Vasc Surg. 1997;26(4):558-569.
60. Bachoo P. Peripheral arterial disease. Clin Evid. 2004(12):144-158.
61. Department of Health, Social Services and Public Safety, Northern Ireland. The primary medical services (direct enhanced services) directions (Northern Ireland) 2008. Belfast: DHSS; 2008. Available online from: http://www.dhsspsni.gov.uk/specification_on_the_primary_medical_services_des_directions_ni_2008.pdf